Objective: Formerly, locally advanced prostate cancer exhibited poorly prognosis. In the late 1990s, new surgical and radiation technologies were introduced in combination with androgen deprivation. To evaluate respective strategies, outcomes were examined. Results: Operation group first started without adjuvant treatment and prostate-specific antigen (PSA) relapse occurred in 39% of cases. Radiation therapy group was alternatively divided into two subgroups, that received either monotherapy or combination with androgen deprivation, and PSA relapse rates were 65 and 16%, respectively. High rates of PSA relapse in both the operation and radiation therapy groups were observed in patients without adjuvant therapy, but after relapse androgen deprivation proceeded favorable outcomes. In the radiation subgroups, PSA relapse rates were different, but both subsequent survival rates were the same. This may be due to the effect of androgen deprivation after relapse, indicating effect of delayed therapy. PSA relapse rate in the hormone therapy group was 25% and after relapse, patients applied to treatment with other hormonal and anticancer drugs. Overall survival rates were 91, 88 and 67% in the operation, radiation therapy and hormone therapy groups, respectively. Conclusion: Aggressive treatment with short-term androgen deprivation for locally advanced prostate cancer could be beneficial and not harmful when suitable candidates are selected. Delayed androgen deprivation was effective for no adjuvant patients after PSA relapse.
Introduction
The incidence of prostate cancer is increasing in Japan, and the mortality rate in the male population will be higher in the future. The treatment of localized prostate cancer yields favorable results in most cases. However, locally advanced prostate cancer, such as Stage T3, contains various properties of tumors, and some tumors show remarkably malignant behavior. There are many treatment opinions and debates about using operative procedures, radiation and medication. Some treatment options consist of monotherapy with one procedure, but most curative procedures are based on multidisciplinary strategies combined with androgen deprivation therapy (ADT).
We treated T3 prostate cancer patients either with operation or radiation therapy combined with/without ADT. In addition, elderly patients or those with comorbidities were treated with ADT alone and referred to as the hormone therapy group. Outcomes managed with various treatments for T3 prostate cancer at a single hospital were reported for comparison.
Materials and methods

Patients
Between 2001 and 2010, 2048 patients with prostate cancer were treated at our hospital. Among them, 224 patients (10.9%) were diagnosed with stage T3N0M0, and their outcomes were followed in the present study after informed consent was obtained. Complete records of patient outcomes were obtained by the end of 2015. The classification of stages was performed according to the National Comprehensive Cancer Network guidelines (1) . Pretreatment biopsy consisted of 12 cores that were performed via the perineal route, and the pathological findings were classified by the Gleason grading system with the ISUP 2005 modification (2). Ultrasonography, magnetic resonance imaging, computed tomography and, if necessary, endoscopy were used for staging. A whole body bone scan was performed in all the patients.
Methods
Retropubic prostatectomy was performed with neoadjuvant ADT for 3 months (operation group). ADT consisted of an luteining-hormonereleasing hormone analog with daily dose of 80 mg bicalutamide. External beam radiation therapy was performed with total doses of 66 Gy with neoadjuvant ADT for 3 months (radiation therapy group). The clinical target volume was defined as the whole prostate. In the hormone therapy group, some patients were elderly or had a Charlson comorbidity score of 0-1 (3).
Total prostate-specific antigen (PSA) was measured using the Architect PSA kit (Abott, Chiba, Japan). PSA was determined every 3 months after the start of treatment. PSA relapse was defined as a linear increase of more than three points from 0.2 ng/ml for the operation group and 2 ng/ml for the other treatment groups. At relapse, patients who did not receive adjuvant treatment were treated with ADT. Patients who relapsed during ADT underwent treatment with other hormonal and anticancer drugs.
Statistical analyses
The SPSS statistical computer program (IBM-SPSS, Inc., Tokyo, Japan) was used for the Kaplan-Meier method, and the difference was calculated by the log-rank test. The Cox proportional hazard model was used with the multivariate analysis for overall survival rate. Student's t-test or Mann-Whitney's U test was used for the difference of clinical factors, and P values were considered significant when P ≤ 0.05. The follow-up time was calculated from the starting date of treatment initiation, with the exception of neoadjuvant ADT.
Results
Stage T3 is definitely separated into a and b by histological finding, but it is alternatively confirmed by digital rectal examination, ultrasonography and radiography, by which most of the patients were examined. Outcomes of patients with T3a differ from those of T3b (Fig. 1 ). This study aims to evaluate the treatment as one advanced stage, the results were calculated with the combination of T3a and b.
Operative specimens were first examined histological examination, and no cancerous tissues were found at the edge of the cutting surfaces. Moreover, no metastases were detected in regional lymph nodes. The extension of tumors through the prostate capsule in the most of the patients was considered, if any, low, thus no adjuvant treatments were scheduled in the operation group. Later, pathological stages of the specimens were confirmed as 16 in pT2, 5 in pT3a and 2 in pT3b; one of the pT3b showed prostate cancer-specific death.
Patients in the radiation therapy group were successively divided into two subgroups. Forty-nine patients who were treated without adjuvant treatment after radiation were the monotherapy subgroup. The other 49 patients who had undergone adjuvant treatment with ADT were the combination subgroup. Adjuvant ADT was scheduled for two or more years. In patients receiving ADT, supplementation with calcium and vitamin D was advised. Patients were inspected for heart disease, hypertension and diabetes by the regular examinations.
In all of the patients, the PSA relapse rates were calculated as 33% at 5 years. The relapse rates in the operation, radiation therapy and hormone therapy groups were 39, 41 and 25%, respectively (Table 1 ). In the radiation therapy group, the relapse rates were 65 and 16% in the monotherapy and combination subgroups, respectively (P = 0.001). Patient characteristics were similar between the subgroups (data not shown). The different rates of PSA relapse might be attributable to the concomitant use of ADT in the combination subgroup. Moreover, considerable patients in the operation group revealed PSA relapse, perhaps due to the absence of the adjuvant therapy in spite of advanced stage. After relapse, treatment with ADT to patients of both the radiation therapy and operation groups proceeded to favorable outcomes. One-fourth of the patients in the hormone therapy group showed PSA relapse, and they gradually entered into the state of castration-resistant prostate cancer.
The overall survival rates were 91, 88 and 67% in the operation, radiation therapy and hormone therapy groups, respectively, at 5 years (Fig. 2) . Patients in the hormone therapy group exhibited a worse prognosis compared with the other two groups (Table 2 ). This may partially influence the patients with advanced age or comorbidities. The causespecific survival rates were 96, 96 and 91% in the operation, radiation therapy and hormone therapy groups, respectively, at 5 years (Fig. 3) , and the hormone therapy group exhibited a slightly lower rate of survival.
In the two radiation therapy subgroups, the overall and cause-specific survival rates were similar to each other (86 and 93% for the overall survival rates and 87 and 93% for the cause-specific survival rates, monotherapy vs combination) regardless of different PSA relapse rates. This suggests that delayed salvage ADT after PSA relapse was effective. The duration between the start of treatment and PSA relapse was similar to each other (Table 1) , and PSA relapse-free survival rates were similar among the three groups: 74, 66 and 75% in the operation, radiation therapy and hormone therapy groups, respectively, at 5 years (Fig. 4) , suggesting that except the patients with PSA relapse the other patients receiving any kind of treatment may proceed in favorable course.
There were no detectable adverse effects in patients undergoing ADT. In addition, no side effects higher than Grade 2 were observed after surgical or radiological procedures.
Discussion
PSA relapse has been reported to occur in 60% of patients with T3 stage prostate cancer 5 years after the start of treatment, which suggests a mortality rate of 70-80% for prostate cancer thereafter. To improve the survival of T3 patients, many strategies have been discussed until now. Patients with T3 stage were surgically examined to confirm negative regional lymph glands, then treated with radiation therapy, and 64% of the patients experienced PSA relapse (4). This indicated that radiation alone did not completely suppress subsequent disease progression. Radical prostatectomy with neoadjuvant ADT for several months was performed (5, 6) . A decrease in stage and a reduction of marginal invasion were found in the specimen of the prostate. Histological changes by ADT were confirmed (7). However, improvement did not continue after subsequent observations (8) (9) (10) . The present study may reveal a similar pattern. After the operation, some Stage T3 patients exhibited PSA relapse and the histological findings of cancer tissues were determined to exhibit a high Gleason pattern (11) .
Radiotherapy for T3 stage prostate cancer was associated with relapse in 60-72% of patients at 5 years (12) . To improve the prognosis, neoadjuvant ADT for 3 months is commonly added to shrink the prostate. High stage patients who did not receive adjuvant hormone therapy frequently experienced PSA relapses, as is observed in the present study. Therefore, adjuvant hormone therapy was recommended. The doses and durations of hormone therapy vary at different institutions. The use of ADT for 2 years or more is recommended for the high-risk patients (13) . We reported that 2 or more years of hormone therapy after carbon ion radiation was associated with favorable results (14) . The radiation dose was 66 Gy in 2 Gy fractions in the present study, and this was commonly used in the reported time frame. Concerning external beam radiation therapy, tremendous progresses including irradiation field and dose by hyperfractionation and hypofractionation have appeared, and a dose of 70 Gy or more was recommended. Moreover, other technologies, such as brachytherapy implants, were distributed. To advanced stage patients, external beam radiation may be favorable because of the wide-spread distribution of irradiation to the whole prostate gland. External beam radiation combined with ADT might reveal better local effects, then increased survival rates (15) (16) (17) . In this study, delayed ADT showed the similar effects on survival as did immediate ADT combined with radiotherapy.
Hormone therapy alone was associated with a 50-60% survival rate at 5 years after the start of treatment (16) . In the Japanese population, better outcomes from ADT monotherapy were reported with mild adverse effects (18) . Although elderly patients or patients with medical comorbidities tended to receive hormone therapy, a worse prognosis was evident (19) .
The pursuit of curative treatment for T3 stage healthy patients is a matter of debate. There have been many reports concerning comparison between operation and radiation therapy with/without ADT. A prospective randomized trial comparing radical prostatectomy and external beam radiation therapy, both with ADT, revealed cause-specific survival rates of 96.6 and 84.6% in patients who had undergone surgery or radiation, respectively, at 5 years (20) . Patients with a low risk showed similar results between two kinds of treatments, but for high-risk patients, long-term outcome appeared to be slightly better results after surgery than after radiotherapy patients (21) (22) (23) (24) . It is impossible to compare exactly the outcome results from many strategies, since states of recipient patients were not coincident with each other. Postoperative stages in operative specimens differ from clinical one to some degree, thus clinical determination shows some bias toward postoperative one. Therefore, when results from many procedures are evaluated, it might be advisable to compare the outcomes from corresponding clinical stage group, which contains some extent of disease states.
Based on the recent progresses in radiation (25) and surgery, patients who were treated by either strategy may achieve similar results (26) . Although exact comparison between surgery and radiation therapy might not be currently available, aggressive treatments were associated with better survival outcomes in healthy patients at high risk when either treatment received (27) , as is obtained in the present study. Every manipulation is on the way of progress, so an aggressive strategy may become more common in the future.
Conclusion
The treatment strategy for a locally advanced stage is varies due to life expectancy, comorbidity and patient intent, but for a suitable candidate, aggressive treatment with short-term ADT may be expected to proceed to favorable outcomes. The application of ADT used in adjuvant or delayed salvage therapies is important considering the duration, dose and adverse effect.
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